Does Medicare Cover Wegovy?
Medicare does not cover Wegovy (semaglutide) for weight loss. The Centers for Medicare & Medicaid Services (CMS) excludes drugs for cosmetic weight loss or reduction from Part D coverage under Section 1860D-2(e)(2)(A) of the Social Security Act.[1] Novo Nordisk's Wegovy labeling specifies its FDA approval for chronic weight management in adults with obesity or overweight with weight-related conditions, which CMS classifies as non-covered.[2]
Coverage for Diabetes Instead?
Wegovy is covered under Medicare Part D if prescribed for its off-label use in type 2 diabetes management, as the identical drug Ozempic (also semaglutide) is FDA-approved for that indication and falls under covered anti-diabetic categories.[3] Prescribers must document diabetes as the primary reason, not weight loss. Some Medicare Advantage plans (Part C) offer broader coverage, but this varies by plan—check via Medicare's Plan Finder tool.[4]
How Does This Compare to Ozempic Coverage?
| Drug | Medicare Part D Coverage | Key Reason |
|------|---------------------------|------------|
| Wegovy | No (weight loss); possible off-label for diabetes | Labeled for weight management only [2] |
| Ozempic | Yes | FDA-approved for type 2 diabetes [5] |
| Zepbound (tirzepatide) | No (weight loss); possible for diabetes as Mounjaro | Similar to Wegovy [6] |
Patients sometimes get Wegovy covered by claiming diabetes, but audits can lead to denials or repayments.
What If You Have Heart Disease?
Wegovy gained a 2024 FDA label expansion for reducing cardiovascular risk in adults with established heart disease and obesity/overweight.[7] Medicare has not updated its policy to cover it for this use, sticking to the weight loss exclusion. CMS issued guidance in 2024 stating anti-obesity drugs remain non-covered, even with new indications.[8]
Alternatives Medicare Pays For
Medicare covers older weight-related drugs like phentermine or Qsymia under Part D if prescribed for obesity with comorbidities, as they predate the exclusion policy.[9] Bariatric surgery is covered under Part B for qualifying patients (BMI ≥35 with conditions).[10] GLP-1s like Ozempic or Trulicity are routinely covered for diabetes.
How to Check Your Specific Coverage
Use Medicare's online Plan Finder (medicare.gov/plan-compare) or call 1-800-MEDICARE. Provide your ZIP code, medications, and conditions. Some states have mandated coverage laws, but they rarely override federal Part D rules. Appeals succeed if diabetes is well-documented.
Cost Without Coverage
A 28-day supply of Wegovy costs $1,300-$1,700 out-of-pocket. Novo Nordisk's savings card caps copays at $25/month for commercial insurance (not Medicare), but eligibility ends after 13 fills.[11] Compounded semaglutide from pharmacies can cost $200-$500/month, though FDA warns of safety risks post-shortage.[12]
Sources
[1]: CMS Medicare Coverage of Anti-Obesity Drugs
[2]: FDA Wegovy Label
[3]: CMS Part D Anti-Diabetic Policy
[4]: Medicare Plan Finder
[5]: FDA Ozempic Label
[6]: CMS Zepbound Memo
[7]: FDA Wegovy CV Update
[8]: CMS 2024 Guidance
[9]: Medicare Weight Loss Drugs
[10]: Medicare Bariatric Surgery
[11]: Novo Savings Card
[12]: [FDA Compounded Semaglutide Alert](https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-risks-associated-compounded-k GLP-1)